PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2049 

Public Law 97-414 

97th Congress An Act 

To amend the Federal Food, Drug, and Cosmetic Act to facilitate the development of Jan. 41 1983 

drugs for rare diseases and conditions, and for other purposes. [H.R. 52381 

Be it enacted by the Senate and House of Representatives of the 

United States of America in Congress assembled, Orphan Drug 

Act. 

SHORT TITLE; FINDINGS 

SECTION 1. (a) This Act may be cited as the "Orphan Drug Act". 21 Usc301 note. 

6) The Congress finds that- 21 USC 360aa 

(1) there are many diseases and conditions, such as Huntington's disease, myoclonus, ALS (Lou Gehrig's disease), Tourette 

syndrome, and muscular dystrophy which affect such small 

numbers of individuals residing in the United States that the 

diseases and conditions are considered rare in the United 

States; 

(2) adequate drugs for many of such diseases and conditions 

have not been developed; (3) drugs for these diseases and conditions are commonly 

referred to as "orphan drugs"; 

(4) because so few individuals are affected by any one rare 

disease or condition, a pharmaceutical company which develops 

an orphan drug may reasonably expect the drug to generate 

relatively small sales in comparison to the cost of developing 

the drug and consequently to incur a financial loss; 

(5) there is reason to believe that some promising orphan 

drugs will not be developed unless changes are made in the 

applicable Federal laws to reduce the costs of developing such 

drugs and to provide financial incentives to develop such drugs; 

and 

(6) it is in the public interest to provide such changes and 

incentives for the development of orphan drugs. 

AMENDMENTS TO THE FEDERAL FOOD, DRUG, AND COSMETIC ACT 

SEC. 2. (a) Chapter V of the Federal Food, Drug, and Cosmetic Act 

is amended by adding at the end the following: 

"RECOMMENDATIONS FOR INVESTIGATIONS OF DRUGS FOR RARE 

DISEASES OR CONDITIONS 

"SEC. 525. (a) The sponsor of a drug for a disease or condition 21 USc 360aa. 

which is rare in the States may request the Secretary to provide written recommendations for the nonclinical and clinical investiga- tions which must be conducted with the drug before- 

"(1) it may be approved for such disease or condition under 

section 505, or 21 usc 355. 
96 STAT. 2050 PUBLIC LAW 97-414-JAN. 4,1983 

42 USC 262. 

"(2) if the drug is a biological product, before it may be 

licensed for such disease or condition under section 351 of the 

Public Health Service Act. 

If the Secretary has reason to believe that a drug for which a 

request is made under this section is a drug for a disease or 

condition which is rare in the States, the Secretary shall provide the 

person making the request written recommendations for the nonclinical and clinical investigations which the Secretary believes, on 

the basis of information available to the Secretary at the time of the 

request under this section, would be necessary for approval of such 

21 USC 355. drug for such disease or condition under section 505 or licensing 

under section 351 of the Public Health Service Act for such disease 

or condition. 

"(b) The Secretary shall by regulation promulgate procedures for the implementation of subsection (a). 

21 USC 360bb. 

Notice. 

"DESIGNATION OF DRUGS FOR RARE DISEASES OR CONDITIONS 

"SEC. 526. (a)(l) The manufacturer or the sponsor of a drug may 

request the Secretary to designate the drug as a drug for a rare 

disease or condition. If the Secretary finds that a drug for which a 

request is submitted under this subsection is being or will be investigated for a rare disease or condition and- 

"(A) if an application for such drug is approved under section 

505, or 

"(B) if the drug is a biological product, a license is issued 

under section 351 of the Public Health Service Act, 

the approval or license would be for use for such disease or condition, the Secretary shall designate the drug as a drug for such 

disease or condition. A request for a designation of a drug under this 

subsection shall contain the consent of the applicant to notice being 

given by the Secretary under subsection (b) respecting the designa- tion of the drug. 

"Rare disease or "(2) For purposes of paragraph (I), the term 'rare disease or 

condition." condition' means any disease or condition which occurs so infrequently in the United States that there is no reasonable expectation 

that the cost of developing and making available in the United 

States a drug for such disease or condition will be recovered from 

sales in the United States of such drug. Determinations under the 

preceding sentence with respect to any drug shall be made on the 

basis of the facts and circumstances as of the date the request for 

designation of the drug under this subsection is made. 

"(b) Notice respecting the designation of a drug under subsection 

(a) shall be made available to the public. "(c) The Secretary shall by -regulation promulgate procedures for the implementation of subsection (a). 

"PROTECTION FOR UNPATENTED DRUGS FOR RARE DISEASES OR 

CONDITIONS 

21 usc 360cc. "SEC. 527. (a) Except as provided in subsection (b), if the Secretary- "(1) approves an application filed pursuant to section 505(b), 

or 

"(2) issues a license under section 351 of the Public Health 

Service Act 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2051 

for a drug designated under section 526 for a rare disease or Ante, P. 2050. 

condition and for which a United States Letter of Patent may not be 

issued, the Secretary may not approve another application under 

section 505(b) or issue another license under section 351 of the 21 Use 355. 

Public Health Service Act for such drug for such disease or condi- 42 USC 262. 

tion for a person who is not the holder of such approved application 

or of such license until the expiration of seven years from the date of 

the approval of the approved application or the issuance of the 

license. Section 505(c)(2) does not apply to the refusal to approve an 

application under the preceding sentence. 

"(b) If an application filed pursuant to section 505(b) is approved 

for a drug designated under section 526 for a rare disease or 

condition or a license is issued under section 351 of the Public 

Health Service Act for such a drug and if a United States Letter of 

Patent may not be issued for the drug, the Secretary may, during 

the seven-year period beginning on the date of the application 

approval or of the issuance of the license, approve another application under section 505(b), or, if the drug is a biological product, issue 

a license under section 351 of the Public Health Service Act, for 

such drug for such disease or condition for a person who is not the 

holder of such approved application or of such license if- 

"(1) The Secretary finds, after providing the holder notice and 

opportunity for the submission of views, that in such period the 

holder of the approved application or of the license cannot 

assure the availability of sufficient quantities of the drug to 

meet the needs of persons with the disease or condition for 

which the drug was designated; or 

"(2) such holder provides the Secretary in writing the consent 

of such holder for the approval of other applications or the 

issuance of other licenses before the expiration of such sevenyear period. 

"OPEN PROTOCOLS FOR INVESTIGATIONS OF DRUGS FOR RARE DISEASES 

OR CONDITIONS 

"SEC. 528. If a drug is designated under section 526 as a drug for a 21 Use 360dd 

rare disease or condition and if notice of a claimed exemption under 

section 505(i) or regulations issued thereunder is filed for such drug, 

the Secretary shall encourage the sponsor of such drug to design 

protocols for clinical investigations of the drug which may be conducted under the exemption to permit the addition to the investigations of persons with the disease or condition who need the drug to 

treat the disease or condition and who cannot be satisfactorily 

treated by available alternative drugs.". 

(b) Chapter V of the Federal Food, Drug, and Cosmetic Act is 

amended by inserting before section 501 the following: 

ORPHAN PRODUCTS BOARD 

SEC. 3. Title I1 of the Public Health Service Act is amended by 

adding at the end the following: 
96 STAT. 2052 PUBLIC LAW 97-414-JAN. 4,1983 

Establishment. "SEC. 227. (a) There is established in the Department of Health 

42 USC 236. and Human Services a board for the development of drugs (including biologics) and devices (including diagnostic products) for rare 

diseases or conditions to be known as the Orphan Products Board. 

The Board shall be comprised of the Assistant Secretary for Health 

of the Department of Health and Human Services and representatives, selected by the Secretary, of the Food and Drug Administration, the National Institutes of Health, the Centers for Disease 

Control, and any other Federal department or agency which the 

Secretary determines has activities relating to drugs and devices for 

rare diseases or conditions. The Assistant Secretary for Health shall 

chair the Board. 

"(b) The function of the Board shall be to promote the development of drugs and devices for rare diseases or conditions and the 

coordination among Federal, other public, and private agencies in 

carrying out their respective functions relating to the development 

of such articles for such diseases or conditions. 

"(c) In the case of drugs for rare diseases or conditions the Board 

Ante, p. 2049. 

21 USC 355. 

42 USC 262. 

shall- 

"(1) evaluate- 

"(A) the effect of subchapter B of the Federal Food, Drug, 

and Cosmetic Act on the development of such drugs, and 

"(B) the implementation of such subchapter; "(2) evaluate the activities of the National Institutes of 

Health and the Alcohol, Drug Abuse, and Mental Health 

Administration for the development of drugs for such diseases 

or conditions, 

"(3) assure appropriate coordination among the Food and 

Drug Administration, the National Institutes of Health, the 

Alcohol, Drug Abuse, and Mental Health Administration, and 

the Centers for Disease Control in the carrying out of their 

respective functions relating to the development of drugs for 

such diseases or conditions to assure that the activities of each 

agency are complementary, "(4) assure appropriate coordination among all interested 

Federal agencies, manufacturers, and organizations representing patients, in their activities relating to such drugs, 

"(5) with the consent of the sponsor of a drug for a rare 

disease or condition exempt under section 50'5(i) of the Federal 

Food, Drug, and Cosmetic Act or regulations issued under such 

section, inform physicians and the public respecting the availability of such drug for such disease or condition and inform 

physicians and the public respecting the availability of drugs 

approved under section 505(c) of such Act or licensed under 

section 351 of this Act for rare diseases or conditions, 

"(6) seek business entities and others to undertake the spon- sorship of drugs for rare diseases or conditions, seek investigators to facilitate the development of such drugs, and seek 

business entities to participate in the distribution of such drugs, 

and 

"(7) recognize the efforts of public and private entities and 

individuals in seeking the development of drugs for rare diseases or conditions and in developing such drugs. 

"(dl The Board shall consult with interested persons respecting the activities of the Board under this section and as part of such 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2053 

consultation shall provide the opportunity for the submission of oral 

views. 

"(el The Board shall submit to the Committee on Labor and Report to 

Human Resources of the Senate and the Committee on Energy and 

Commerce of the House of Representatives an annual report- 

"(1) identifying the drugs which have been designated under 

section 526 of the Federal Food, Drug, and Cosmetic Act for a 

rare disease or condition, 

"(2) describing the activities of the Board, and 

"(3) containing the results of the evaluations carried out by 

the Board. 

The Director of the National Institutes of Health and the Administrator of the Alcohol, Drug Abuse, and Mental Health Administration shall submit to the Board for inclusion in the annual report a 

report on the rare disease and condition research activities of the 

Institutes of the National Institutes of Health and the Alcohol, Drug 

Abuse, and Mental Health Administration; the Secretary of the 

Treasury shall submit to the Board for inclusion in the annual 

report a report on the use of the credit against tax provided by 

section 44H of the Internal Revenue Code of 1954; and the Secretary Znfra 

of Health and Human Services shall submit to the Board for inclusion in the annual report a report on the program of assistance 

under section 5 of the Orphan Drug Act for the development of post) P. '70% 

drugs for rare diseases and conditions. Each annual report shall be 

submitted by June 1 of each year for the preceding calendar year.". 

TAX CREDIT FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR 

CONDITIONS 

SEC. 4. (a) Subpart A of part IV of subchapter A of chapter 1 of the 

Internal Revenue Code of 1954 (relating to credits allowable) is 

amended by inserting after section 44G the following new section: 

"SEC. 44H. CLINICAL TESTING EXPENSES FOR CERTAIN DRUGS FOR RARE 26 USC d4H. 

DISEASES OR CONDITIONS. 

"(a) GENERAL RULE.-There shall be allowed as a credit against 

the tax imposed by this chapter for the taxable year an amount 

equal to 50 percent of the qualified clinical testing expenses for the 

taxable year. 

"(b) QUALIFIED CLINICAL TESTING EXPENSES.-For purposes of this 

section- 

"(1) QUALIFIED CLINICAL TESTING EXPENSES.- 

"(A) IN GENERAL.-Except as otherwise provided in this 

paragraph, the term 'qualified clinical testing expenses' 

means the amounts which are paid or incurred by the 

taxpayer during the taxable year which would be described 

in subsection (b) of section 44F if such subsection were 

applied with the modifications set forth in subparagraph 03). "(B) MODIFICATIONS.-For purposes of subparagraph (A), 

subsection (b) of section 44F shall be applied- 

"(i) by substituting 'clinical testing' for 'qualified 

research' each place it appears in paragraphs (2) and (3) 

of such subsection, and 

"(ii) by substituting '100 percent' for '65 percent' in 

paragraph (3)(A) of such subsection. 
96 STAT. 2054 PUBLIC LAW 97-414-JAN. 4,1983 

21 USC 355. 

Ante, p. 2050. 

"(C) EXCLUSION FOR AMOUNTS FUNDED BY GRANTS, ETC.- 

The term 'qualified clinical testing expenses' shall not include any amount to the extent such amount is funded by 

any grant, contract, or otherwise by another person (or any 

governmental entity). "(D) SPECIAL RULE.-For purposes of this paragraph, section 44F shall be deemed to remain in effect for periods 

after December 31,1985. 

"(2) CLINICAL TESTING.- 

"(A) IN GENERAL.-The term 'clinical testing' means any human clinical testing- "(i) which is carried out under an exemption for a drug being tested for a rare disease or condition under 

section 505(i) of the Federal Food, Drug, and Cosmetic 

Act (or regulations issued under such section), 

"(ii) which occurs- 

"(I) after the date of such drug is designated 

under section 526 of such Act, and 

"(11) before the date on which an a plication with respect to such drug is approved un er section 

505(b) of such Act, and 

a 

"(iii) which is conducted by or on behalf of the taxpayer to whom the designation under such section 526 

applies. 

"(B) TESTING MUST BE RELATED TO USE FOR RARE DISEASE OR 

coN~1~1oN.-Human clinical testing shall be taken into 

account under subparagraph (A) only to the extent such 

testing is related to the use of a drug for the rare disease or 

condition for which it was designated under section 526 of 

the Federal Food, Drug, and Cosmetic Act. 

"(c) COORDINATION WITH CREDIT FOR INCREASING RESEARCH EXPENDITURES.- 

"(1) IN GENERAL.-Except as provided in paragraph (21, any qualified clinical testing expenses for a taxable year to which an 

election under this section applies shall not be taken into 

account for purposes of determining the credit allowable under 

section 44F for such taxable year. "(2) EXPENSES INCLUDED IN DETERMINING BASE PERIOD RESEARCH EXPENSES.--Any qualified clinical testing expenses for 

any taxable year which are qualified research expenses (within the meaning of section 44F(b)) shall be taken into account in 

determining base period research expenses for purposes of ap- plying section 44F to subsequent taxable years. "(dl DEFINITION AND SPECIAL RULES.- 

"(1) RARE DISEASE OR CONDITION.--For purposes of this section, 

the term 'rare disease or condition' means any disease or condition which occurs so infrequently in the United States that 

there is no reasonable expectation that the cost of developing and making available in the United States a drug for such 

disease or condition will be recovered from sales in the United 

States of such drug. Determinations under the preceding sen- tence with respect to any drug shall be made on the basis of the 

facts and circumstances as of the date such drug is designated under section 526 of the Federal Food, Drug, and Cosmetic Act. 

"(2) LIMITATION BASED ON AMOUNT OF TAX.-The credit allowed by this section for any taxable year shall not exceed the 

amount of the tax imposed by this chapter for the taxable year 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2055 

reduced by the sum of the credits allowable under a section of 

this subpart having a lower number or letter designation than 

this section, other than the credits allowable by sections 31, 39, 

and 43. For purposes of the preceding sentence, the term 'tax 

imposed by this chapter' shall not include any tax treated as not 

imposed by this chapter under the last sentence of section 53(a). 

"(3) SPECIAL LIMITATIONS ON FOREIGN TESTING.- 

"(A) IN GENERAL.-NO credit shall be allowed under this 

section with respect to any clinical testing conducted outside the United States unless- 

"(i) such testing is conducted outside the United 

States because there is an insufficient testing popula- tion in the United States, and 

"(ii) such testing is conducted by a United States 

person or by any other rson who is not related to the 

taxpayer to whom the k esignation under section 526 of 

the Federal Food, Drug, and Cosmetic Act applies. "(B) SPECIAL LIMITATION FOR CORPORATIONS TO WHICH SECTION 934 (b) OR 936 APPLIES.-NO credit shall be allowed 

under this section with respect to any clinical testing conducted by a corporation to which section 934(b) applies or to 

which an election under section 936 applies. "(4) CERTAIN RULES MADE APPLICABLE.-Rules similar to the 

rules of paragraphs (1) and (2) of section 44F(fl shall apply for 

purposes of this section. 

"(5) ELECTION.-T~~S section shall apply to any taxpayer for 

any taxable year only if such taxpayer elects (at such time and 

in such manner as the Secretary may b regulations prescribe) 

to have this section apply for such taxab r e year. "(el TERMINATION.-This section shall not apply to any amount 

paid or incurred after December 31,1987." 

(b)(l) Section 280C of such Code (relating to denial of deduction for 26 USC 280C 

portion of wages for which credit is claimed under section 40 or 44B) 

is amended by adding at the end thereof the following new subsection: 

"(c) CREDIT FOR QUALIFIED CLINICAL TESTING EXPENSES FOR CERTAIN DRUGS.- 

"(1) IN GENERAL.-NO deduction shall be allowed for that 

portion of the qualified clinical testing expenses (as defined in 

section 44H(b)) otherwise allowable as a deduction for the taxable vear which is eaual to the amount of the credit allowable 

for the taxable yeai under section 44H (determined without 

regard to subsection (dI(2) thereof). 

"(2) SIMILARULE WHERE TAXPAYER CAPITALIZES RATHER THAN 

DEDUCTS EXPENSES.-If- 

"(A) the amount of the credit allowable for the taxable 

year under section 44H (determined without regard to subsection (d)(2) thereofl, exceeds 

"(B) the amount allowable as a deduction for the taxable 

year for qualified clinical testing expenses (determined without regard to paragraph (111, 

the amount chargeable to capital account for the taxable year for such expenses shall be reduced by the amount of such 

excess. 

"(3) CONTROLLED GROUPS.-In the case of a corporation which is a member of a controlled group of corporations (within the 

meaning of section 44F(D(5)) or a trade or business which is 
96 STAT. 2056 PUBLIC LAW 97-414-JAN. 4, 1983 

treated as being under common control with other trades or 

business (within the meaning of section 44F(fl(l)(B)), this subseo 

tion shall be applied under rules prescribed by the Secretary 

similar to the rules applicable under subparagraphs (A) and (B) 

of section 44F(f)(l)." 

(2)(A) The section heading of section 280C of such Code is amended 

to read as follows: 

"SEC. 280C. CERTAIN EXPENSES FOR WHICH CREDITS ARE ALLOWABLE." 

(B) The table of sections for part IX of subchapter B of chapter 1 of 

such Code is amended by striking out the item relating to section 

280C and inserting in lieu thereof the following: 

"Sec. 280C. Certain expenses for which credits are allowable." 

(c)(l) The table of sections for subpart A of part IV of subchapter A 

of chapter 1 of such Code is amended by inserting after the item 

relating to section 44G the following new item: 

"Sec. 44H. Clinical testing expenses for certain drugs for rare diseases or 

conditions." 

26 uSC 6096. (2) Subsection (b) of section 6096 of such Code is amended by 

striking out "and 44G and inserting in lieu thereof "44G, and 44H' . 26 usc 44H (d) The amendments made by this section shall apply to amounts 

note paid or incurred after December 31, 1982, in taxable years ending 

after such date. 

GRANTS AND CONTRACTS FOR DEVELOPMENT OF DRUGS FOR RARE 

DISEASES AND CONDITIONS 

21 USC 360ee. 

"Qualified 

clinical 

testing." 

Ante, p. 2050 

21 USC 355. 

"Rare disease or condition." 

SEC. 5. (a) The Secretary may make grants to and enter into 

contracts with public and private entities and individuals to assist in 

defraying the costs of qualified clinical testing expenses incurred in 

connection with the development of drugs for rare diseases and 

conditions. 

(b) For purposes of subsection (a): 

(1) The term "qualified clinical testing'' means any human 

clinical testing- 

(A) which is carried out under an exemption for a drug for a rare disease or condition under section 505(i) of the 

Federal Food, Drug, and Cosmetic Act (or regulations issued 

under such section), 

(B) which occurs- 

(i) after the date such drug is designated under section 526 of such Act, and 

(ii) before the date on which an application with 

respect to such drug is submitted under section 505(b) 

of such Act. 

(2) The term "rare disease or condition" means any disease or 

condition which occurs so infrequently in the United States that 

there is no reasonable expectation that the cost of developing and making available in the United States a drug for such 

disease or condition will be recovered from sales in the United 

States of such drug. Determinations under the preceding sentence with respect to any drug shall be made on the basis of the 

facts and circumstances as of the date the request for designa- tion of the drug under this subsection is made. 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2057 

(c) For grants and contracts under subsection (a) there are author- Appropriation 

ized to be appropriated $4,000,000 for fiscal year 1983 and for each of authorization 

the next two fiscal years. 

HOME HEALTH SERVICES 

SEC. 6. (a) Part D of title I11 of the Public Health Service Act is 

amended by inserting after subpart I1 the following new subpart: 

"HOME HEALTH SERVICES 

"SEC. 339. (a)(l) For the purpose of encouraging the establishment Grants. 

and initial operation of home health programs to provide home 42USC 255. 

health services in areas in which such services are inadequate or not 

readily accessible, the Secretary may, in accordance with the provisions of this section, make grants to public and nonprofit private 

entities and loans to proprietary entities to meet the initial costs of 

establishing and operating such home health programs. Such grants 

and loans may include funds to provide training for paraprofessionals (including homemaker home health aides) to provide home 

health services. 

"(2) In making grants and loans under this subsection, the Secretary shall- 

"(A) consider the relative needs of the several States for home 

health services; 

"(B) give preference to areas in which a high percentage of 

the population proposed to be served is composed of individuals 

who are elderly, medically indigent, or disabled; and 

"(C) give special consideration to areas with inadequate 

means of transportation to obtain necessary health services. 

"(3)(A) No loan may be made to a proprietary entity under this 

section unless the application of such entity for such loan contains 

assurances satisfactory to the Secretary that- 

"(i) at the time the application is made the entity is fiscally 

sound; 

''(ii) the entity is unable to secure a loan for the project for 

which the application is submitted from non-Federal lenders at 

the rate of interest prevailing in the area in which the entity is 

located; and 

"(iii) during the period of the loan, such entity will remain 

fiscally sound. 

"(B) Loans under this section shall be made at an interest rate 

comparable to the rate of interest prevailing on the date the loan is 

made with respect to the marketable obligations of the United 

States of comparable maturities, adjusted to provide for administrative costs. 

"(4) Applications for grants and loans under this subsection shall 

be in such form and contain such information as the Secretary shall 

prescribe. 

"(5) There are authorized to be appropriated for grants and loans Appropriation 

under this subsection $5,000,000 for each of the fiscal years ending authorizatlOn. 

on September 30,1983, and September 30,1984. 

"(b)(l) The Secretary may make grants to and enter into contracts 

with public and private entities to assist them in developing appro- 
96 STAT. 2058 PUBLIC LAW 97-414-JAN. 4,1983 

priate training programs for paraprofessionals (including homemaker home health aides) to provide home health services. 

"(2) Any program established with a grant or contract under this 

subsection to train homemaker home health aides shall- 

"(A) extend for at least forty hours, and consist of classroom 

instruction and at least twenty hours (in the aggregate) of 

supervised clinical instruction directed toward preparing students to deliver home health services; 

"(B) be carried out under appropriate professional supervision and be designed to train students to maintain or enhance the 

personal care of an individual in his home in a manner which 

promotes the functional independence of the individual; and 

"(C) !~clude training in- 

(i) personal care services designed to assist an individual 

in the activities of daily living such as bathing, exercising, 

personal grooming, and getting in and out of bed; and 

"(ii) household care services such as maintaining a safe 

living environment, light housekeeping, and assisting in 

providing good nutrition (by the purchasing and preparation of food). 

"(3) In making grants and entering into contracts under this 

subsection, special consideration shall be given to entities which 

establish or will establish programs to provide training for persons fifty years of age and older who wish to become paraprofessionals 

(including homemaker home health aides) to provide home health 

services. 

"(4) Applications for grants and contracts under this subsection 

shall be in such form and contain such information as the Secretary 

shall prescribe. Appropriation "(5) There are authorized to be appropriated for grants and conauthorization. tracts under this subsection $2,000,000 for each of the fiscal years 

ending September 30,1983, and September 30,1984. 

Report to "(c) The Secretary shall report to the Committee on Labor and 

Human Resources of the Senate and the Committee on Energy and committees. Commerce of the House of Representatives on or before January 1, 

1984, with respect to- 

"(1) the impact of grants made and contracts entered into 

under subsections (a) and (b) (as such subsections were in effect 

prior to October 1,1981); 

"(2) the need to continue grants and loans under subsections 

(a) and (b) (as such subsections are in effect on the day after the 

date of enactment of the Orphan Drug Act); and 

"(3) the extent to which standards have been applied to the 

training of personnel who provide home health services. 

"(dl For purposes of this section, the term 'home health services' 

has the meaning prescribed for the term by section 1861(m) of the 

42 USC 1395~. Social Security Act.". 

Report and (b) The Secretary shall report the results of studies currently recommends- evaluating home and community based health services, and any tions to 

Congress. recommendations for legislative action which might improve the 

42 usc 255 note. provision of such services, to the Congress prior to January 1, 1985. 

42 USC 255 note. (c) The Secretary of Health and Human Services shall compile and 

analyze the results of significant studies carried out by any public or 

private entity, group, or individual, relating to current and alternative reimbursement methodologies for home health services. The 

Secretary shall make recommendations with respect to such reimbursement methodologies as they might be applied in health care 
PUBLIC LAW 97-414-JAN. 4,1983 96 STAT. 2059 

programs funded in whole or in part by Federal funds, and report 

such recommendations to the Congress within 180 days after the 

date of the enactment of this Act. 

(d) The Secretary of Health and Human Services, acting through Investigation. 

the Inspector General of the Department of Health and Human 42 USC 255 note. 

Services, shall undertake a thorough investigation of- 

(1) the methods available to stem fraud and abuse in the 

provision of home health services under medicare and medicaid; 

and 

(2) the extent to which such methods are applied in stemming 

such fraud and abuse. 

The Secretary shall report the results of the investigation to the Report to 

Congress within 18 months after the date of the enactment of this Congress. 

Act. 

(e)(l) The Secretary of Health and Human Services shall develop 42 USC 255 note. 

and carry out demonstration projects commencing no later than 

January 1,1984, to test- 

(A) methods for identifying patients at risk of institutionalization who could be treated more cost-effectively with 

home health services and other non-institutional health services; and 

(B) alternative reimbursement methodologies for home health 

agencies in order to determine the most cost-effective and efficient way of providing home health services. 

(2) Methods for identifying patients at risk of institutionalization 

to be tested by the Secretary under paragraph (1)(A) may include, 

but not be limited to, the identification of hospitalized medicare 

patients who are candidates for early discharge due to availability of 

home health services and individuals in the community who could 

avoid institutionalization with the availability of home health 

services. 

(3) Reimbursement methodologies to be tested by the Secretary 

under paragraph (l)(B) may include but not be limited to fee schedules, prospective reimbursement, and capitation payments. 

(4) The Secretary shall report to Congress his findings with regard Rep0rt to 

to the demonstrations carried out under paragraph (1) no later than 

January 1,1985. 

(f) For purposes of this section, the term "home health services'' "Home health 

has the meaning prescribed for the term by section 1861(m) of the g";ei55 note, Social Security Act. 42 USC 1395~. 

ANALYSIS OF THYROID CANCER; ACTIONS BY SECRETARY 

SEC. 7. (a) In carrying out section 301 of the Public Health Service 42 USC 241 note. 

Act, the Secretary of Health and Human Services shall- 42 usc 241. 

(1) conduct scientific research and prepare analyses necessary 

to develop valid and credible assessments of the risks of thyroid 

cancer that are associated with thyroid doses of Iodine 131; 

(2) conduct scientific research and prepare analyses necessary 

to develop valid and credible methods to estimate the thyroid 

doses of Iodine 131 that are received by individuals from nuclear 

bomb fallout; 

(3) conduct scientific research and prepare analyses necessary 

to develop valid and credible assessments of the exposure to 

Iodine 131 that the American people received from the Nevada 

atmospheric nuclear bomb tests; and 
96 STAT. 2060 PUBLIC LAW 97-414-JAN. 4,1983 

Report to (4) prepare and transmit to the Congress within one year after 

Congress. the date of enactment of this Act a report with respect to the 

activities conducted in carrying out paragraphs (I), (21, and (3). 

Radioepidemi- (b)(l) Within one year after the date of enactment of this Act, the olOgical Secretary of Health and Human Services shall devise and publish publication. radioepidemiological tables that estimate the likelihood that persons who have or have had any of the radiation related cancers and who 

have received specific doses prior to the onset of such disease 

developed cancer as a result of these doses. These tables shall show a 

probability of causation of developing each radiation related cancer 

associated with receipt of doses ranging from 1 millirad to 1,000 rads 

in terms of sex, age at time of exposure, time from exposure to the 

onset of the cancer in question, and such other categories as the 

Secretary, after consulting with appropriate scientific experts, deter- mines to be relevant. Each probability of causation shall be calculated and displayed as a single percentage figure. (2) At the time the Secretary of Health and Human Services 

publishes the tables pursuant to paragraph (I), such Secretary shall 

also publish- 

(A) for the tables of each radiation related cancer, an evaluation which will assess the credibility, validity, and degree of 

certainty associated with such tables; and 

(B) a compilation of the formulas that yielded the probabil- ities of causation listed in such tables. Such formulas shall be 

published in such a manner and together with information 

necessary to determine the probability of causation of any 

individual who has or has had a radiation related cancer and 

has received any given dose. 

(3) The tables specified in paragraph (1) and the formulas specified 

in paragraph (2) shall be devised from the best available data that 

are most applicable to the United States, and shall be devised in 

accordance with the best available scientific procedures and exper- tise. The Secretary of Health and Human Services shall update these tables and formulas every four years, or whenever he deems it 

necessary to insure that they continue to represent the best available scientific data and expertise. 

Update of 

tables. 

TECHNICAL AMENDMENTS TO THE PUBLIC HEALTH SERVICE ACT 

SEC. 8. (a) Section 207(a)(l) of such Act (42 U.S.C. 209(a)(l)) is 

amended by inserting "psychology," after "pharmacy,". 

(b) Section 306(1)(2) of such Act (42 U.S.C. 242k(1)(2)) is amended 

by striking out subparagraph (Dl and redesignating subparagraphs (E), (F), and (G) as subparagraphs (Dl, (E), and (F), respectively. (c) Section 308(d) of such Act (42 U.S.C. 242m(d)) is amended (1) by inserting ", if an establishment or person supplying the information 

or described in it is identifiable," after "No information", and (2) by striking out "authorized by guidelines in effect under section 

306(1)(2) or under regulations of the Secretary" and inserting in lieu 

thereof "such establishment or person has consented (as determined 

under regulations of the Secretary) to its use for such other 

purpose". 

(dl The first sentence of section 311(c)(2) of such Act (42 U.S.C. 

243(c)(2)) is amended by striking out "forty-five days'' and inserting 

instead "six months". 

(el Section 330(dJ(2) of such Act (42 U.S.C. 254c(d)(2)) is amended by inserting before "and the costs" the following: ", the costs of repay- 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2061 

ing loans made by the Farmers Home Administration for 

buildings,". (fl Section 337(a) of such Act (42 U.S.C. 254j(a)) is amended by 

striking out "carrying out this subpart" and inserting in lieu thereof 

"carrying out this subpart (other than section 338G)". 

(g)(l) Section 338B(e) of the Public Health Service Act (42 U.S.C. 

254m-(el) is amended by inserting before the period the following: "or under section 225 as in effect on September 30,1977". 

(2) Section 338D(b) of such Act (42 U.S.C. 294w(b)) is amended by 42 USC 2540. 

striking out "section 338F6)" and inserting in lieu thereof "section 

338E(d)". 

(3) Section 338E(d)(l) of such Act (42 U.S.C. 294x(d)(l)) is amended 42 USC 254~ 

by striking out "section 338D(c)" and inserting in lieu thereof 

"section 338D(bjV. 

(h) Section 340(g) of the Public Health Service Act (42 U.S.C. 

256(g)) is amended (1) by striking out "and" after "1980," in para- graph (1) and by inserting before the period in that paragraph a 

comma and "and $3,000,000 for the fiscal year ending September 30, 

1982", and (2) by inserting "and" after "1980," in paragraph (2) and 

by striking out in that paragraph ", and $3,000,000 for the fiscal 

year ending September 30,1982". 

(i) Section 737(2) of such Act (42 U.S.C. 294j(2)) is amended by 

inserting "in a State" after "means a school". 

(j) Section 781(a)(2) of such Act (42 U.S.C. 295g-l(a)(2)) is amended 

by striking out "under area health education center programs". 

(k)(l) Section 791A(b)(3)(A) of such Act (42 U.S.C. 295h-la(b)(3)(A)) 

is amended by striking out "postbaccalaureate" and inserting in lieu 

thereof "baccalaureate". 

(2) Section 791(c)(2)(A) of such Act (42 U.S.C. 295h(c)(2)(A)) is 

amended to read as follows: 

"(A) such application contains assurances satisfactory to the 

Secretary that in the school year (as defined in regulations of 

the Secretary) beginning in the fiscal year for which the applicant receives a grant under subsection (a) that- 

"(i) at least 25 individuals will complete the graduate educational programs of the entity for which such application is submitted; and 

"(ii) such entity shall expend or obligate at least $100,000 

in funds from non-Federal sources to conduct such programs; and". 

(1) Section 8316) of such Act (42 U.S.C. 297-l(b)) is amended by 

inserting before the period a comma and the following: "$400,000 for 

the fiscal year ending September 30,1983, and $800,000 for the fiscal 

year ending September 30,1984". 

(m) Title VIII of such Act is amended by adding at the end thereof 

the following: 

'(TECHNICAL ASSISTANCE 

"SEC. 857. Funds appropriated under this title may be used by the 42 USC 298b-4. 

Secretary to provide technical assistance in relation to any of the 

authorities under this title.". 

(n) Sections 1001(c), 1003(b), and 1005(b) of such Act (42 U.S.C. 

300(c), 300a-161, 300a-36)) are each amended by striking out the 

comma after "1981" and inserting in lieu thereof a semicolon. 

(0) Section 1101(b) of such Act (42 U.S.C. 300b(b)) (as in effect 

before its repeal by section 21936)(1) of the Omnibus Budget Reconciliation Act of 1981 is amended by inserting a comma after "1981". 95 Stat. 826 
96 STAT. 2062 PUBLIC LAW 97-414-JAN. 4, 1983 

95 Stat. 571. 

(p) Section 1536 of such Act (42 U.S.C. 300n-5) (as amended by section 935 of the Omnibus Budget Reconciliation Act of 1981) is 

amended by striking out "this title and" and inserting in lieu 

thereof "this title and-". 

42 USC 300~1-2. (q) Section 1602(fl(2) of such Act (42 U.S.C. 300g-2(f)(2)) is amended 

by inserting after "including" the following: "selling real property 

pledged as security for such a loan or loan guarantee and". 

(r)(l) The matter in section 1706(a) (42 U.S.C. 300u-5(a)) of the 

Public Health Service Act preceding paragraph (1) is amended by striking out "Health Information, Health Promotion and Physical Fitness and Sports Medicine" and inserting instead "Health promotion". (2) The section heading for section 1706 of such Act (42 U.S.C. 

3001.1-5) is amended to read as follows: 

42 USC 300x. 

42 USC 241. 

42 USC 2689 

note, 9401 

note. 

42 USC 241. 

42 USC 4571, 

4578. 

95 Stat. 595. 

21 USC 1176, 

1177. 

"OFFICE OF HEALTH PROMOTION". 

(s) The second sentence of section 1904(a)(l)(F) of such Act (42 

U.S.C. 300~-3(a)(l)(F)) isamended by striking out "equipment for the systems" and inserting in lieu thereof "equipment for the 

systems (other than systems with respect to which grants were made 

as prescribed by section 1905(c)(2))". (t) Effective October 1, 1982, section 1912(b) of such Act (42 U.S.C. 

300x-l(b)) is amended to read as follows: 

"(b)(l) From the remainder of the amount appropriated under section 1911 for any fiscal year, the Secretary shall allot to each 

State an amount which bears the same ratio to such remainder for 

that fiscal year as the amounts- 

"(A) which would have been provided by the Secretary to the 

State and entities in the State under section 301 of this Act for 

mental health services demonstrations and under the Community Mental Health Centers Act and the Mental Health Systems Act for mental health services for fiscal year 1981 if the Secretary had obligated all the funds for such purposes available for such Acts under Public Law 96-536, and 

"(B) provided by the Secretary to the State and entities in the 

State under the laws referred to in subparagraphs (Dl and (E) of 

paragraph (2) for fiscal year 1980, 

bore to the total amount appropriated for mental health services 

demonstrations and mental health services for fiscal year 1981 

under Public Law 96-536 for section 301 of this Act, the Community Mental Health Centers Act and the Mental Health Systems Act and 

the total amount appropriated for fiscal year 1980 for the provisions of law referred to in subparagraphs (Dl and (El of paragraph (2). "(2) The provisions of law referred to in paragraph (1) are the 

following provisions of law as in effect on the day before the date of 

the enactment of the Omnibus Budget Reconciliation Act of 1981: 

"(A) The Community Mental Health Centers Act. 

"(B) The Mental Health Systems Act. 

"(C) Section 301 of this Act. 

"(D) Sections 301 and 312 of the Comprehensive Alcohol 

Abuse and Alcoholism, Prevention, Treatment, and Rehabilitation Act of 1970. 

"(El Sections 409 and 410 of the Drug Abuse Prevention, 

Treatment, and Rehabilitation Act. 

"(3) For purposes of paragraph (11, the total amount appropriated under Publlc Law 96-536 for mental health services demonstrations 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2063 

under section 301 of this Act shall be deemed not to exceed 

$20,000,000; and if such total amount did exceed $20,000,000, the 

amount that would have been provided to each State and entities in 

each State shall be ratably reduced for purposes of paragraph (l)(A) 

to conform to the limit prescribed by this paragraph. 

"(4) To the extent that all the funds appropriated under section 

1911 for a fiscal year and available for allotment in such fiscal year 

are not otherwise allotted to States because- 

"(A) one or more States have not submitted an application or 

description of activities in accordance with section 1915 for the 42 USC 300~-4 

fiscal year; "(B) one or more States have notified the Secretary that they 

do not intend to use the full amount of their allotment; or 

"(C) some State allotments are offset or repaid under section 

1916(b)(3); 42 USC 3OOx-5. 

such excess shall be allotted among each of the remaining States in 

proportion to the amount otherwise allotted to such States for the 

fiscal year without regard to this paragraph.". 

(u)(l) section 1915(c)(5) of such Act (42 U.S.C. 300x-4(~)(5)) is 

amended (1) by inserting "procedures for" before "procedural", and 

(2) by striking out "review procedures" and inserting in lieu thereof 

"review". 

(2)(A) Section 1915(c)(6)(A)(i) of such Act (42 U.S.C. 300x4(c)(6)(A)(i)) isamended- 

(i) by striking out "for mental health services"; 

(ii) by inserting "for mental health services" after "fiscal year 

1981"; 

(iii) by inserting "for mental health services demonstrations 

under section 301 of this Act" before "if the Secretary"; and 

(iv) by striking out "such Acts" each place it occurs and 

inserting in lieu thereof "such provisions of law". 

(B) Section 1915(c)(6)(A)(ii) of such Act (42 U.S.C. 300~-4(~)(6)(A)(ii)) 

is amended- 

(i) by striking out "for mental health services"; 

(ii) by inserting "for mental health services" after "fiscal year 

1981"; 

(iii) by inserting "and for mental health services demonstrations under section 301 of this Act" before "if the Secretary"; 

and 

(iv) by striking out "such Acts" and inserting in lieu thereof 

"such provisions of law". 

(v) Section 1932 of such Act is amended by- 95 Stat. 559 

(1) inserting "(a)" after "1932.", and 42 USC 300~-11. 

(2) adding a new subsection (b) as follows: 

"(b) The Secretary shall promulgate separate regulations govern- Regulations. 

ing the administration of this part. Such regulations shall take into 

account the distinctive features of the grant program authorized 

under this part.". 

(w) From the funds appropriated under section 419B of such Act 42 USC 287i 

or under any other applicable provision of law, the Secretary of T;lt&c 287i, Health and Human Services shall provide for the development and 

support of not less than ten comprehensive centers for sickle cell 

disease. 
96 STAT. 2064 PUBLIC LAW 97-414-JAN. 4,1983 

95 Stat. 572. 

42 USC 300m. 

95 Stat. 573. 

42 USC 300e-1. 

95 Stat. 593. 

42 USC 4577. 

95 stat. 593. 

95 Stat. 594. 

42 USC 4588. 

95 Stat. 922. 

42 USC 295g-4. 

Repeal. 

42 USC 3OOt-11 

note. 

MISCELLANEOUS TECHNICAL AMENDMENTS 

SEC. 9. (a) Section 931(a) of the Omnibus Budget Reconciliation Act 

of 1981 is amended by striking out " '1980,' " in paragraphs (I), (21, 

and (3) and inserting in lieu thereof" '1980;' ". 

(b) Section 936(b)(l) of the Omnibus Budget Reconciliation Act of 

1981 is amended by striking out "300m(d)(l)(B)(ii)" and inserting in 

lieu thereof "300m(d)(l)(B)". 

(c) Section 942(i) of the Omnibus Budget Reconciliation Act of 1981 

is amended by striking out " 'feasible (1)' " and inserting in lieu 

thereof" 'feasible (i)' ". 

(d)(l) Section 963(b)(4) of the Omnibus Budget Reconciliation Act 

of 1981 is amended by striking out "clause (2)" and inserting in lieu 

thereof "clause (3)". 

(2) Section 311(a)(3) of the Comprehensive Alcohol Abuse and 

Alcoholism Prevention, Treatment, and Rehabilitation Act of 195'0 

(42 U.S.C. 4577(b)3)) is amended by striking out the period at the end 

and inserting in lieu thereof a comma. 

(el Section 965(a) of the Omnibus Budget Reconciliation Act of 

1981 is amended by striking out paragraph (A) and by redesignating 

paragraphs (B), (C), and (Dl as paragraphs (11, (21, and (3), 

respectively. (fl Section 2741(a)(3) of the Omnibus Budget Reconciliation Act of 

1981 is amended by striking out "and 'and' ". 

(g)(l) Section 709 of the Controlled Substances Act (21 U.S.C. 904) 

is amended (1) by striking out subsections (a) and (b), (2) by striking 

out "(c)", and (3) by amending the section heading to read as follows: 

"PAYMENT OF TORT CLAIMS". 

(2) The item relating to section 709 in the table of contents of the 

Comprehensive Drug Abuse Prevention and Control Act of 1970 is 

amended by striking out "Authorizations of Appropriations" and 

inserting in lieu thereof "Payment of Tort Claims". 

(h) Section 302 of the Health Planning and Resources Development Amendments of 1979 (Public Law 96-79) is repealed. 

(i) The paragraph beginning with "Service and supply fund:" 

under the heading "PUBLIC HEALTH SERVICE" in the Federal 

Security Agency Appropriation Act, 1946 (42 U.S.C. 2311 is amended 

by inserting ", or in advance," after "stock furnished". 

Cj)(l) Section 6Cb)(l) of the Consumer Product Safety Act (15 U.S.C. 

2055(b)(1)) is amended by striking out "paragraph (2)" and inserting 

in lieu thereof "paragraph (4)". 

(2) Section ll(c) of such Act (15 U.S.C. 2060(c)) is amended by striking out "section 10(e)(4)" and inserting in lieu thereof "subsection (fl". 

(31 Section 15(g)(l) of such Act (15 U.S.C. 2064(g)(l)) is amended by 

striking out "section 12(c)(l)" and inserting in lieu thereof "12(d)(l)' . (4)(A) Section 19(a)(7) of such Act (15 U.S.C. 2068(a)(7)) is amended 

by striking out "section 9(d)(2)" and inserting in lieu thereof "section 9(g)(2)lV. 

(B) Paragraph (8) of section 19(a) of such Act is repealed and 

paragraph (9) and the first of the two paragraphs (10) are redesignated as paragraphs (8) and (91, respectively. 

(5) Section 31(b)(l) of such Act (15 U.S.C. 2080(b)(l)) is amended by striking out "The Commission'' and all that follows through "Substances Act," and inserting in lieu thereof the following: 
PUBLIC LAW 97-414-JAN. 4, 1983 96 STAT. 2065 

"(bX1) The Commission may not issue- 

"(A) an advance notice of proposed rulemaking for a consumer product safety rule, 

"(B) a notice of proposed rulemaking for a rule under section 

27(e), or 

"(C) an advance notice of proposed rulemaking for regulations 

under section 2(q)(l) of the Federal Hazardous Substances 

Act,". 15 USC 1261. 

(k) Section 3(a) of the Poison Prevention Packaging Act of 1970 (15 

U.S.C. 1472(a)) is amended by striking out ", after consultation with 

the Technical Advisory Committee provided for in section 6 of this 

Act". 

(1) Section 15 of the Federal Hazardous Substances Act (15 U.S.C. 

1274) (as amended by section 1211(0(1) of the Omnibus Budget Reconciliation Act of 1982) is amended by adding at the end thereof 95 Stat. 721. 

the following: 

"(el For purposes of this section (1) the term 'manufacturer' "Manufacturer." 

includes an importer for resale, and (2) a dealer who sells at 

wholesale an article or substance shall with respect to that sale be 

considered the distributor of that article or substance.". 

(m) Section 1211(h)(4) of the Omnibus Budget Reconciliation Act of 

1981 is amended by striking out "by inserting ', Science and Trans- 95 Stat. 721. 

portation' immediately after 'on Commerce', and". 15 usc 2064. 

STUDY 

SEC. 10. Of the funds available under section 706 of the Energy Security Act, there shall be made available $800,000 for the costs of 42 USC 8905. 

a grant or contract for a study of the water quality of the Quabbin 

Reservoir in Massachusetts. 

PATENT TERM EXTENSION 

SEC. 11. (a) Title 35, United States Code, is amended by adding the 

following new section: 

"9 155. Patent term extension 35 USC 155. 

"Notwithstanding the provisions of section 154, the term of a 35 USC 154. 

patent which encompasses within its scope a composition of matter 

or a process for using such composition shall be extended if such 

composition or process has been subjected to a regulatory review by the Federal Food and Drug Administration pursuant to the Federal 

Food, Drug, and Cosmetic Act leading to the publication of regula- 21 USC 301. 

tion permitting the interstate distribution and sale of such composition or process and for which there has thereafter been a stay of 

regulation of approval imposed pursuant to section 409 of the 

Federal Food, Drug, and Cosmetic Act which stay was in effect on 21 USc 348. 

January 1, 1981, by a length of time to be measured from the date 

such stay of regulation of approval was imposed until such proceedings are finally resolved and commercial marketing permitted. The 

patentee, his heirs, successors or assigns shall notify the Commissioner of Patents and Trademarks within ninety days of the date of 

enactment of this section or the date the stay of regulation of 

approval has been removed, whichever is later, of the number of the 

patent to be extended and the date the stay was imposed and the 

date commercial marketing was permitted. On receipt of such 

notice, the Commissioner shall promptly issue to the owner of record 
96 STAT. 2066 PUBLIC LAW 97-414-JAN. 4,1983 

of the patent a certificate of extension, under seal, stating the fact 

and length of the extension and identifying the composition of 

matter or process for using such composition to which such extension is applicable. Such certificate shall be recorded in the official 

file of each patent extended and such certificate shall be considered 

as part of the original patent, and an appropriate notice shall be 

published in the Official Gazette of the Patent and Trademark 

Office.". 

tb) The analysis for chapter 14 of such title 35 is amended by 

adding at the end the following: 

"135. Patent term extension.". 

Approved January 4,1983. 

LEGISLATIVE HISTORY-H.R. 5238: 

HOUSE REPORT No. 97-840 Pt. I (Comm. on Energy and Commerce). 

CONGRESSIONAL RECORD, Vol. 128 (1982): 

Sept. 28, considered and passed House. 

Oct. 1, considered and passed Senate, amended. 

Dec. 14, House concurred in Senate amendment with an amendment. 

Dec. 16, Senate concurred in House amendment. 

WEEKLY COMPILATION OF PRESIDENTIAL DOCUMENTS, Vol. 19, No. 1 (1983): 

Jan. 4, Presidential statement.